Peter Ellingworth

Peter leads the Association of British HealthTech Industries (ABHI), the UK’s leading HealthTech trade association, representing 280 companies in MedTech, diagnostics and digital health. ABHI advocates industry’s needs at senior government level, supports UK market access, informs on commercial matters, provides regulatory advice, promotes ethical compliance and develops international trade opportunities for SMEs.

Representing industry across government, Peter currently sits on the Secretary of State led Life Sciences Council, and the sector specific Health Technology Partnership which supports it.

At European Level, Peter is a board member of MedTech Europe and is the immediate past Chair of their National Association Network (NAN). Internationally, he is engaged with the UK Government on several initiatives to promote the country and assist British companies with their export strategies.

Having previously served as the interim Chair of the Greater Manchester Academic Health Science Network (AHSN), Peter currently sits on the Board of the Oxford AHSN, and leads work to enhance collaboration between ABHI Members and the AHSN national network, most recently through the newly constituted MedTech Innovation National Network. In 2014, he also chaired the Health Economy work stream of the London Health Commission, established by the Mayor of London and Lord Ara Darzi.

Peter has 35 years’ experience in sales, marketing and general management in the UK and across Europe and as a non-executive director of early stage companies. He is also a proud member of the 30% Club, which campaigns for greater representation of women at senior leadership and board level, with a target of a minimum of 30%.

As ABHI celebrates its 30th anniversary today, Peter Ellingworth, Chief Executive of the association discusses the past, present and future. 1. In the 30-year history of ABHI, what have been the biggest changes? Our industry has changed significantly over the last 30 years, from being simply product based, to delivering value-based service solutions and increasingly incorporating new fields of science, utilising digital data, AI and robotics. Our rebrand this year has reflected that: Association of British HealthTech Industries. We have invested in the senior leadership team, who are all contemporary industry professionals and are experts in the field of procurement, reimbursement, market access, HTA, health policy and NHS relations. We have refreshed the leadership in our regulatory and technical area and continue to build our deep relations with the MHRA and the notified bodies. Our international business has developed widely, manning the UK pavilions at global exhibitions and developing a comprehensive programme of trade missions with a strong focus on the US, and providing a programme of accelerator hubs. 2. How does ABHI engage with policymakers and legislators? The strength of ABHI’s network is one of our defining assets. We are focused at a senior level across several government departments, Parliamentarians in both Houses that are relevant to HealthTech, deep relationships with the NHS, regulators in both health and technical matters, and with the academic health science community. We represent industry on a number of high-level government forums: the Life Sciences Council, the Life Sciences Industrial Strategy Implementation Board, the EU Relationship Group, and the Health Technology Partnership. This year we formalised our relationship with a number of major cities’ health and academic communities, through a series of Memorandum of Understandings. This affords our members exceptional access to the NHS for collaboration on research, right through to adoption and spread...
The medical technology industry creates over half a million different products, from pacemakers and artificial hips to condoms and pregnancy tests. Despite the impact these products have on millions of people of all ages every day, medtech is still a little known and often misunderstood sector. With European MedTech Week now in its second year, we want to change this. From 13-17 June, the MedTech sector is hosting activities across the continent to raise awareness of the industry and the life-changing innovation we invest in and provide. MedTech Week is a chance for the entire healthcare community to discuss the future of Europe’s health and how medical technology can address current challenges and ensure more sustainable pathways of care. There is a lot that we can do. The medtech sector is at the cutting edge of research and development. It employs some of the world’s most skilled doctors, engineers, and scientists. From prevention to diagnosis, treatment and cure medtech innovations are absolutely crucial to public health and patient wellbeing. For my part, I also see MedTech Week as an opportunity to reinforce our industry’s commitment to high ethical standards. Our sector works closely with healthcare professionals to develop new and innovative technologies that drive improvements in patient care. Commitment to a robust Code of Ethical Business Practice safeguards these important relationships. This is why MedTech Europe recently endorsed an updated ‘Code’ which applies both to device and diagnostic companies. The Code provides a clear framework for open and transparent interactions between industry and healthcare professionals, ensuring that patients can continue to benefit from these collaborations. The medtech industry partners with all types of professionals on a daily basis so I am delighted that this year, the dedicated website for European MedTech Week www.medtechweek.eu will feature their perspectives, along with those...